Literature DB >> 30474474

SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice.

Karthik M Kodigepalli1, Minghua Li1, Serena Bonifati1, Amanda R Panfil1, Patrick L Green1,2,3, Shan-Lu Liu1,4, Li Wu1,3,4.   

Abstract

Sterile alpha motif and HD domain-containing protein 1 (SAMHD1) is a mammalian dNTP hydrolase (dNTPase) and functions as a negative regulator in the efficacy of cytarabine treatment of acute myeloid leukemia (AML). We have reported that SAMHD1 knockout (KO) increased the activity of phosphoinositide 3-kinase (PI3K) in AML-derived THP-1 cells and attenuated their ability to form subcutaneous tumors in xenografted immunodeficient mice. However, the functional significance of SAMHD1 in controlling AML leukemogenesis remains unclear. Previous studies show that in vitro transformation of Madin-Darby canine kidney (MDCK) epithelial cells by the Jaagsiekte sheep retrovirus (JSRV) envelope protein requires activation of the PI3K/Akt oncogenic signaling pathway. Using this cell transformation model, we demonstrated that ectopic expression of wild-type human SAMHD1 or a dNTPase-defective SAMHD1 mutant (HD/AA) significantly inhibited MDCK cell transformation, but did not affect cell proliferation. To visualize and quantify THP-1 cell growth and metastasis in xenografted immunodeficient mice, we generated luciferase-expressing stable SAMHD1 KO THP-1 cells and control THP-1 cells, which were injected intravenously into immunodeficient mice. Bioluminescence imaging and quantification analysis of xenografted mice revealed that SAMHD1 KO cell-derived tumors had similar growth and metastatic potential compared with control cells at 35 days post-injection. However, mice xenografted with SAMHD1 KO cells showed greater survival compared with mice injected with control cells. Our data suggest that exogenous SAMHD1 expression suppresses in vitro cell transformation independently of its dNTPase activity, and that endogenous SAMHD1 affects AML tumorigenicity and disease progression in vivo.

Entities:  

Keywords:  PI3K-Akt signaling; SAMHD1; acute myeloid leukemia (AML); cell transformation; immunodeficient mice xenograft; retrovirus oncogene

Mesh:

Substances:

Year:  2018        PMID: 30474474      PMCID: PMC6300106          DOI: 10.1080/15384101.2018.1550955

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  54 in total

1.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.

Authors:  Deepa Sampath; Jorge Cortes; Zeev Estrov; Min Du; Zheng Shi; Michael Andreeff; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

Review 2.  Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.

Authors:  Jiri Polivka; Filip Janku
Journal:  Pharmacol Ther       Date:  2013-12-09       Impact factor: 12.310

3.  MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.

Authors:  Rebecca Kohnken; Karthik M Kodigepalli; Anjali Mishra; Pierluigi Porcu; Li Wu
Journal:  Leuk Res       Date:  2016-11-17       Impact factor: 3.156

4.  Direct transformation of rodent fibroblasts by jaagsiekte sheep retrovirus DNA.

Authors:  N Maeda; M Palmarini; C Murgia; H Fan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

5.  Downregulation of SAMHD1 expression correlates with promoter DNA methylation in Sézary syndrome patients.

Authors:  Suresh de Silva; Feifei Wang; Timothy S Hake; Pierluigi Porcu; Henry K Wong; Li Wu
Journal:  J Invest Dermatol       Date:  2013-07-24       Impact factor: 8.551

6.  The jaagsiekte sheep retrovirus envelope gene induces transformation of the avian fibroblast cell line DF-1 but does not require a conserved SH2 binding domain.

Authors:  Thomas E Allen; Kate J Sherrill; Sara M Crispell; Matthew R Perrott; Jonathan O Carlson; James C DeMartini
Journal:  J Gen Virol       Date:  2002-11       Impact factor: 3.891

7.  SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.

Authors:  Constanze Schneider; Thomas Oellerich; Hanna-Mari Baldauf; Sarah-Marie Schwarz; Dominique Thomas; Robert Flick; Hanibal Bohnenberger; Lars Kaderali; Lena Stegmann; Anjali Cremer; Margarethe Martin; Julian Lohmeyer; Martin Michaelis; Veit Hornung; Christoph Schliemann; Wolfgang E Berdel; Wolfgang Hartmann; Eva Wardelmann; Federico Comoglio; Martin-Leo Hansmann; Alexander F Yakunin; Gerd Geisslinger; Philipp Ströbel; Nerea Ferreirós; Hubert Serve; Oliver T Keppler; Jindrich Cinatl
Journal:  Nat Med       Date:  2016-12-19       Impact factor: 53.440

8.  SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates.

Authors:  Hichem Lahouassa; Waaqo Daddacha; Henning Hofmann; Diana Ayinde; Eric C Logue; Loïc Dragin; Nicolin Bloch; Claire Maudet; Matthieu Bertrand; Thomas Gramberg; Gianfranco Pancino; Stéphane Priet; Bruno Canard; Nadine Laguette; Monsef Benkirane; Catherine Transy; Nathaniel R Landau; Baek Kim; Florence Margottin-Goguet
Journal:  Nat Immunol       Date:  2012-02-12       Impact factor: 25.606

Review 9.  Targeting the phosphoinositide 3-kinase pathway in cancer.

Authors:  Pixu Liu; Hailing Cheng; Thomas M Roberts; Jean J Zhao
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

10.  Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.

Authors:  Jinfeng Liu; William Lee; Zhaoshi Jiang; Zhongqiang Chen; Suchit Jhunjhunwala; Peter M Haverty; Florian Gnad; Yinghui Guan; Houston N Gilbert; Jeremy Stinson; Christiaan Klijn; Joseph Guillory; Deepali Bhatt; Steffan Vartanian; Kimberly Walter; Jocelyn Chan; Thomas Holcomb; Peter Dijkgraaf; Stephanie Johnson; Julie Koeman; John D Minna; Adi F Gazdar; Howard M Stern; Klaus P Hoeflich; Thomas D Wu; Jeff Settleman; Frederic J de Sauvage; Robert C Gentleman; Richard M Neve; David Stokoe; Zora Modrusan; Somasekar Seshagiri; David S Shames; Zemin Zhang
Journal:  Genome Res       Date:  2012-10-02       Impact factor: 9.043

View more
  4 in total

1.  SAMHD1, positively regulated by KLF4, suppresses the proliferation of gastric cancer cells through MAPK p38 signaling pathway.

Authors:  Zhangming Chen; Zhe Jiang; Lei Meng; Ye Wang; Minggui Lin; Zhijian Wei; Wenxiu Han; Songcheng Ying; Aman Xu
Journal:  Cell Cycle       Date:  2022-06-07       Impact factor: 5.173

2.  Mouse model recapitulates the phenotypic heterogeneity of human adult T-cell leukemia/lymphoma in bone.

Authors:  Nicole A Kohart; Said M Elshafae; Wachirapan Supsahvad; Aylin Alasonyalilar-Demirer; Amanda R Panfil; Jingyu Xiang; Wessel P Dirksen; Deborah J Veis; Patrick L Green; Katherine N Weilbaecher; Thomas J Rosol
Journal:  J Bone Oncol       Date:  2019-08-20       Impact factor: 4.072

Review 3.  Dual roles of SAMHD1 in tumor development and chemoresistance to anticancer drugs.

Authors:  Zhangming Chen; Jie Hu; Songcheng Ying; Aman Xu
Journal:  Oncol Lett       Date:  2021-04-08       Impact factor: 2.967

4.  Evolved Resistance to Placental Invasion Secondarily Confers Increased Survival in Melanoma Patients.

Authors:  Yasir Suhail; Junaid Afzal
Journal:  J Clin Med       Date:  2021-02-05       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.